Nuclear data measurements at the upgraded neutron time-of-flight facility n-TOF at CERN

Applications of nuclear data like neutron-induced reaction cross sections are related to research fields as stellar nucleosynthesis, the study of nuclear level densities and strength functions, and also play a key role in the safety and criticality assessment of existing and future nuclear reactors, in areas concerning radiation dosimetry, medical applications, transmutation of nuclear waste, accelerator-driven systems and fuel cycle investigations. The evaluations in nuclear data libraries are based both on experimental data and theoretical models. CERN's neutron time-of-flight facility n-TOF has produced a considerable amount of experimental data since it has become fully operational with the start of its scientific measurement programme in 2002. While for a long period a single measurement station (EAR1) located at 185 m from the neutron production target was available, the construction of a second beam line at 20 m (EAR2) in 2014 has substantially increased the measurement capabilities of the facility. An outline of the experimental nuclear data activities at CERN's neutron time-of-flight facility n-TOF will be presented

Serpentine differentiation and polyploid evolution in \kur{Knautia arvensis} agg. (Dipsacaceae).

Evolutionary history of an intricate polyploid complex Knautia arvensis agg. in Central Europe has been studied using combined approach of molecular (AFLP, DNA-sequencing) and cytological (flow cytometry, karyology) techniques. Possible evolutionary scenario has been suggested for the whole complex and for the serpentine population in particular, based on critical assessment of results obtained from the different methods

Nuclear astrophysics at n-TOF facility, CERN

The innovative feature of the n-TOF facility at CERN, in the two experimental areas, (20 m and 200 m flight paths), allow for an accurate determination of the neutron capture cross section for radioactive samples or for isotopes with small neutron capture cross section, of interest for Nuclear Astrophysics. This contribution presents an overview on the astrophysical program carried on at the n-TOF facility, the main results and their implications

The PREDICTS database: a global database of how local terrestrial biodiversity responds to human impacts.

Biodiversity continues to decline in the face of increasing anthropogenic pressures such as habitat destruction, exploitation, pollution and introduction of alien species. Existing global databases of species' threat status or population time series are dominated by charismatic species. The collation of datasets with broad taxonomic and biogeographic extents, and that support computation of a range of biodiversity indicators, is necessary to enable better understanding of historical declines and to project - and avert - future declines. We describe and assess a new database of more than 1.6 million samples from 78 countries representing over 28,000 species, collated from existing spatial comparisons of local-scale biodiversity exposed to different intensities and types of anthropogenic pressures, from terrestrial sites around the world. The database contains measurements taken in 208 (of 814) ecoregions, 13 (of 14) biomes, 25 (of 35) biodiversity hotspots and 16 (of 17) megadiverse countries. The database contains more than 1\% of the total number of all species described, and more than 1\% of the described species within many taxonomic groups - including flowering plants, gymnosperms, birds, mammals, reptiles, amphibians, beetles, lepidopterans and hymenopterans. The dataset, which is still being added to, is therefore already considerably larger and more representative than those used by previous quantitative models of biodiversity trends and responses. The database is being assembled as part of the PREDICTS project (Projecting Responses of Ecological Diversity In Changing Terrestrial Systems - http://www.predicts.org.uk). We make site-level summary data available alongside this article. The full database will be publicly available in 2015

NSC86062

The (n,gamma) cross section of Au-197 has been measured at n_TOF in the resolved resonance region, up to 5 keV, with the aim of improving the accuracy in an energy range where it is not yet considered standard. The measurements were performed with two different experimental setup and detection techniques, the total energy method based on C6D6 detectors, and the total absorption calorimetry based on a 4 pi BaF2 array. By comparing the data collected with the two techniques, two accurate sets of neutron-capture yields have been obtained, which could be the basis for a new evaluation leading to an extended cross-section standard. Overall good agreement is found between the n_TOF results and evaluated cross sections, with some significant exceptions for small resonances. A few resonances not included in the existing databases have also been observed

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, 656 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful